Top Markets
Coin of the day
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
株式のランク #33517
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
株価
$0.0794724
時価総額
$7.49M
変化(1日)
4.69%
変化(1年)
-38.28%
DE
取引 TME Pharma N.V. (ALTME)

カテゴリー

TME Pharma N.V.(ALTME)のP/B比率
2026 時点のP/B比率 TTM: 0
TME Pharma N.V. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
TME Pharma N.V. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE